Navigation Links
Cytopia Merger with Toronto-based YM BioSciences Inc.
Date:10/5/2009

and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter a Phase 1/II clinical study in 2009.

About YM

YM BioSciences Inc. is a life sciences product development company that identifies and advances a portfolio of promising cancer-related products at various stages of development. The Company is currently developing two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM), and AeroLEF®, a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

About YM Programs

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is significantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in more than 20 countries. In more than 5,000 patients reported as having been treated with nimotuzumab worldwide to date, no Grade IV incidents of radiation dermatitis have been described, severe rash has not been observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been rare. Nimotuzumab is licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology.

YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using fentanyl because patients can individually control the analgesia required for their differing intensities o
'/>"/>

SOURCE Cytopia Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY
2. Cytopia Presentation on VDA CYT997 at AACR Conference
3. Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference
4. Cytopia Letter to Progen Shareholders
5. Cytopia and Other Progen Shareholders Maintain Call for Meeting
6. Presentation on Cytopias JAK2 Inhibitor Program in Myeloproliferative Disorders
7. Cytopia Strengthens Scientific Team With US-Based Drug Development Specialist
8. Cytopia Presentation on JAK2 Inhibitor at American Association for Cancer Research
9. Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger
10. Schering-Plough Shareholders Approve Merger With Merck
11. TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... Ohio (PRWEB) April 27, 2015 ... of an agreement with Joslin Diabetes Center (“Joslin”) ... 2b study of Diasome’s novel Hepatocyte Directed Vesicle ... Type 1 diabetes. , Located in Boston, ... clinical care and education organization dedicated to the ...
(Date:4/24/2015)... and Tempe, AZ (PRWEB) April 24, 2015 ... and Arizona State University (ASU) have entered into an ... projects. , A memorandum of agreement signed by the ... distance learning, student success and other services particularly, though ... , “We have complementary strengths and a similar ...
(Date:4/24/2015)... MONTREAL , April 24, 2015 /CNW Telbec/ - Mirego, ... part of the making of three mobile app extensions for ... for its clients, Familiprix, OMSignal and MediaMiser, these ... information thanks to functions designed specifically for wrist use.  ... the Apple Watch is a highly customizable tactile smartwatch that ...
(Date:4/23/2015)... CA (PRWEB) April 23, 2015 Athena ... personal development of executive women in San Diego’s technology ... the 17th Annual Pinnacle Awards at their Gala on ... Hyatt Hotel. Register now at http://athenasd.org/events/ , ... support the Athena San Diego vision of fostering networking, ...
Breaking Biology Technology:Diasome Pharmaceuticals Announces Clinical Trial Design Collaboration 2South Dakota Mines, Arizona State University Pave Way for Cooperative Research 2Familiprix, OMSignal and MediaMiser apps available today for Apple Watch 2Athena Pinnacle Awards to Honor Executives, Corporations and Educators Working to Promote Women Leaders 2
... 5 Dynamic Alert,Limited (OTC Bulletin Board: DYMC) ... its target markets for its pharmaceutical product line-up. ... for enhancing rapid onset,through oromucosal absorption, topical applications, ... internal use. Some products will have,specific uses, while ...
... Dec. 5 Early clinical experience with the FDA,cleared ... of ultrasound guided cryoablation to completely eradicate,small, unifocal Invasive ... study was presented at the 94th Scientific Assembly and ... November 29 -,December 5, 2008. , ...
... Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Alternext ... Agreement with the http://www.senesco.com ("Harris Moran") has ... recently announced corporate restructuring. , ... parent company, Limagrain, restructured its vegetable seed operations and ...
Cached Biology Technology:Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products 2Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products 3Cryoablation of Early Invasive Ductal Breast Cancer With MRI Confirmation Shows Promising Clinical Benefits, According to Study Presented at RSNA 2Cryoablation of Early Invasive Ductal Breast Cancer With MRI Confirmation Shows Promising Clinical Benefits, According to Study Presented at RSNA 3Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring 2Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring 3
(Date:4/8/2015)... , April 8, 2015  Infinisource, a leading ... services, and Morpho, a leading supplier of biometric ... produce the market,s most advanced biometrically-enabled time clock, ... NXG time clock is setting a bold, new ... data for the small and mid-size employer. When ...
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... of Pennsylvania School of Medicine & School of Engineering ... deliver drugs to tumors. By using a cylindrical-shaped carrier ... paclitaxel to an animal model of lung cancer ten ... findings have implications for drug delivery as well as ...
... vitamin was named, what is known about them ... public health, says Irwin Rosenberg, MD, University Professor, ... at the Jean Mayer USDA Human Nutrition Research ... on his presentation at the National Institutes of ...
... was published in an advance online edition of the Proceedings ... April 9, 2007. , The study provides new evidence that ... is activated by the protein SGT1, which also activates Resistance ... pathogens. The study also confirms structural similarities between the Nod1 ...
Cached Biology News:Penn researchers show how nanocylinders deliver medicine better than nanospheres 2Vitamins: Science doesn't always match policy 2Scripps research study shows humans and plants share common regulatory pathway 2Scripps research study shows humans and plants share common regulatory pathway 3
... service is for when you need to make ... their transformation efficiency. Our services for preparing competent ... applications. MCLab's custom competent cell service offers: ... Fast turnaround Quality control ...
... WR Cryoscope for molecular weight determinations for petroleum-based applications. Multiple solvents can be used, such ... ... ... ...
Growth Medium / Media...
... Sensitivity Laboratory Osmometer for 50 L samples. Operating head automatically rises at the end of determination; triple-point ... ... ... ...
Biology Products: